University Health Network Princess Margaret Cancer Centre
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Easson, Alexandra M
NCT01837225: ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI and Eagle Imaging Devices

Recruiting
N/A
90
Canada
University Health Network, Toronto
Breast Cancer
08/25
08/25
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
Elimova, Elena
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
NCT06043427: Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Recruiting
2
168
Canada
Paclitaxel, Ramucirumab, Zanidatamab
Canadian Cancer Trials Group, Jazz Pharmaceuticals
Gastroesophageal Adenocarcinoma
12/25
06/26
SLC-0111-17-01, NCT03450018: A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

Terminated
1/2
6
Canada
SLC-0111, WBI-5111, Gemcitabine Injection, Gemcitabine
British Columbia Cancer Agency, Canadian Cancer Society (CCS), SignalChem Lifesciences Corporation
Metastatic Pancreatic Ductal Adenocarcinoma
05/24
05/24
MOCHA, NCT04219137: Molecular Characteristics of Gastroesophageal Adenocarcinoma (): A Prospective Feasibility Study

Recruiting
N/A
120
Canada
Molecular Profiling, Whole Genome Sequencing
University Health Network, Toronto
Esophagogastric Adenocarcinoma
11/25
11/25
MASST, NCT03712566: Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

Active, not recruiting
N/A
39
Canada
University Health Network, Toronto
Cancer, Esophagus Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Anal Canal Squamous Cell Carcinoma, Metastatic Cancer
12/25
12/25

Download Options